Giant Papillary Conjunctivitis
Giant papillary conjunctivitis (GPC), also called contact lens–induced papillary conjunctivitis (CLPC), is a common complication of contact lens wear. First described by Spring, [1, 2, 3, 4] GPC is characterized by hypersensitivity-related inflammation of the ocular tarsal palpebral conjunctivae.  It is associated with the use of all types of contact lenses (eg, rigid, hydrogel, silicone hydrogel, piggyback,  scleral, prosthetic), although similar reactions have been noted with ocular prostheses, extruding scleral buckles, exposed ocular sutures, and even elevated corneal scars.
GPC was once considered an allergic disease similar to other immunoglobulin E (IgE)–mediated ocular allergy such as allergic conjunctivitis and vernal keratoconjunctivitis because of the similar clinical symptoms seen in allergic diseases (eg, itchiness, tearing, mucous hyperproduction, increase in symptoms during allergy season). The mechanical irritation of contact lenses and sutures that causes GPC supports the classification of GPC into a group of nonallergic hypersensitivity disorders. 
Initially, small papillae coalesce with expanding internal collections of inflammatory cells. When the lesions reach diameters of more than 0.3 mm, often approaching or exceeding 1 mm, the condition is referred to as GPC. Images of eyelid papillae appear below.
Because of the high prevalence of GPC among contact lens wearers, GPC should be considered in every patient with characteristic symptoms who wears contact lenses.
See the following for more information:
The antigen(s) responsible for GPC have yet to be identified. From circumstantial evidence, the initiating event is believed to be mechanical irritation and/or antigenic stimulus of the tarsal conjunctiva of the upper lids by a contact lens surface or edge (rigid or flexible) or deposit. Histologic changes in the tissue occur with mast cell degranulation and a secondary inflammatory cascade. This leads to conjunctivitis and further tissue changes with increasing inflammatory markers in the tears.
GPC can be caused by all forms of ocular prostheses, including rigid and hydrogel (soft) contact lenses, prosthetic eyes, extruding scleral buckles, exposed portions of sutures, filters, knots, and even corneal scars.  Heat sterilization, poor cleaning, thick or rough contact lens edges, and extended wearing times also predispose to the development of GPC.
Lipid and protein deposits from the tears, as well as debris coating the surface of contact lenses, may also lead to a spiral of inflammation. This, in turn, causes even more lens deposits to form, leading to additional inflammation. [1, 2, 3] The level of coating on the lenses varies among individuals and the polymer of the contact lenses.
High-water hydrogel (HEMA) contact lenses tend to coat more than lower-water HEMA contact lenses. Silicone contact lenses tend to accumulate more lipid deposits than HEMA lenses. First-generation silicone hydrogel contact lenses may be more prone to GPC development, perhaps because of their mechanical stiffness or their higher propensity for lipid deposition. Silicone hydrogel lenses tend to induce more local GPC (similar to the changes seen with rigid lenses), whereas hydrogel lenses tend to induce more generalized GPC reactions in the palpebral conjunctiva. 
In the United States, the prevalence of GPC is highest among wearers of hydrogel contact lenses—approximately 20%. Rigid gas-permeable contact lens wearers constitute approximately 5% of all cases. One study found that 85% of 221 patients with GPC had been wearing hydrogel lenses, whereas only 15% used rigid lenses.  With an increased frequency of contact lens replacement from more than four weeks to less than four weeks, the incidence of GPC has dropped from 36% to 4.5%.  This rate should drop even lower with the greater availability and popularity of one-day disposable contact lenses.
The international prevalence of GPC is similar to that in the United States.
Both sexes develop GPC.
GPC can be more aggressive in children who wear contact lenses.
The prognosis of GPC is good. Approximately 80% of patients can return to comfortable contact lens wear with appropriate treatment. 
GPC has been a common cause of temporary and permanent contact lens intolerance. It can also cause ptosis of the upper lids.
The lids of some patients return to normal appearance following the resolution of GPC, whereas other lids retain small, white, capped scars of the giant papillary lesions for long periods, sometimes indefinitely.
GPC is not associated with mortality.
Patients should be educated about appropriate contact lens cleaning and follow-up care. Regular professional evaluations (perhaps once or twice a year in the absence of other complications) and additional appointments are recommended if they experience any increasing ocular itching, mucous discharge, or dirty contact lenses.
Patients should also be educated about the chronic nature of GPC and its symptoms (eg, ocular itch, mucous discharge, contact lens intolerance). Patients should be counseled to present within a week of any relapsing symptoms.
Allansmith MR, Korb DR, Greiner JV. Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology. 1978 Aug. 85(8):766-78. [Medline].
Allansmith MR, Ross RM. Giant papillary conjunctivitis. Int Ophthalmol Clin. 1988. 28(4):309-16.
Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am. 2008 Feb. 28(1):83-103, vi. [Medline].
Spring TF. Reaction to hydrophilic lenses. Med J Aust. 1974 Mar 23. 1(12):449-50. [Medline].
Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012 Nov. 67 (11):1327-37. [Medline].
Forister JF, Forister EF, Yeung KK, Ye P, Chung MY, Tsui A, et al. Prevalence of contact lens-related complications: UCLA contact lens study. Eye Contact Lens. 2009 Jul. 35(4):176-80. [Medline].
García-Posadas L, Contreras-Ruiz L, Soriano-Romaní L, Dartt DA, Diebold Y. Conjunctival Goblet Cell Function: Effect of Contact Lens Wear and Cytokines. Eye Contact Lens. 2016 Mar. 42 (2):83-90. [Medline].
Dunn JP Jr, Weissman BA, Mondino BJ, Arnold AC. Giant papillary conjunctivitis associated with elevated corneal deposits. Cornea. 1990 Oct. 9(4):357-8. [Medline].
Skotnitsky CC, Naduvilath TJ, Sweeney DF, Sankaridurg PR. Two presentations of contact lens-induced papillary conjunctivitis (CLPC) in hydrogel lens wear: local and general. Optom Vis Sci. 2006 Jan. 83 (1):27-36. [Medline].
Porazinski AD, Donshik PC. Giant papillary conjunctivitis in frequent replacement contact lens wearers: a retrospective study. CLAO J. 1999 Jul. 25 (3):142-7. [Medline].
Donshik PC, Ballow M, Luistro A, Samartino L. Treatment of contact lens-induced giant papillary conjunctivitis. CLAO J. 1984 Oct-Dec. 10(4):346-50. [Medline].
Tagliaferri A, Love TE, Szczotka-Flynn LB. Risk factors for contact lens-induced papillary conjunctivitis associated with silicone hydrogel contact lens wear. Eye Contact Lens. 2014 May. 40 (3):117-22. [Medline].
Allansmith MR, Korb DR, Greiner JV, Henriquez AS, Simon MA, Finnemore VM. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol. 1977 May. 83(5):697-708. [Medline].
Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002 Feb. 37 (1):21-6. [Medline].
Greiner JV, Covington HI, Allansmith MR. Surface morphology of the human upper tarsal conjunctiva. Am J Ophthalmol. 1977 Jun. 83(6):892-905. [Medline].
Szczotka LB, Cocuzzi E, Medof ME. Decay-accelerating factor in tears of contact lens wearers and patients with contact lens-associated complications. Optom Vis Sci. 2000 Nov. 77(11):586-91. [Medline].
Ballow M, Donshik PC, Rapacz P, Samartino L. Tear lactoferrin levels in patients with external inflammatory ocular disease. Invest Ophthalmol Vis Sci. 1987 Mar. 28(3):543-5. [Medline].
Rapacz P, Tedesco J, Donshik PC, Ballow M. Tear lysozyme and lactoferrin levels in giant papillary conjunctivitis and vernal conjunctivitis. CLAO J. 1988 Oct-Dec. 14(4):207-9. [Medline].
Elgebaly SA, Donshik PC, Rahhal F, Williams W. Neutrophil chemotactic factors in the tears of giant papillary conjunctivitis patients. Invest Ophthalmol Vis Sci. 1991 Jan. 32(1):208-13. [Medline].
Irkeç MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm. 1999 Mar. 7(1):35-8. [Medline].
Moschos MM, Eperon S, Guex-Crosier Y. Increased eotaxin in tears of patients wearing contact lenses. Cornea. 2004 Nov. 23(8):771-5. [Medline].
Abelson MB, Soter NA, Simon MA, Dohlman J, Allansmith MR. Histamine in human tears. Am J Ophthalmol. 1977 Mar. 83(3):417-8. [Medline].
Donshik PC, Ballow M. Tear immunoglobulins in giant papillary conjunctivitis induced by contact lenses. Am J Ophthalmol. 1983 Oct. 96(4):460-6. [Medline].
Ballow M, Donshik PC, Mendelson I. Complement proteins and C3 anaphylatoxin in the tears of patients with contact lens associated conjunctivitis. J Allergy Clin Immunol. 1985. 76(3):473-6.
Zhong X, Liu H, Pu A, Xia X, Zhou X. M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis. Arch Immunol Ther Exp (Warsz). 2007 May-Jun. 55(3):173-7. [Medline]. [Full Text].
Korb DR, Greiner JV, Finnemore VM, Allansmith MR. Treatment of contact lenses with papain. Increase in wearing time in keratoconic patients with papillary conjunctivitis. Arch Ophthalmol. 1983 Jan. 101(1):48-50. [Medline].
Bartlett JD, Howes JF, Ghormley NR, Amos JF, Laibovitz R, Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res. 1993 Apr. 12(4):313-21. [Medline].
Khurana S, Sharma N, Agarwal T, Chawla B, Velpandian T, Tandon R, et al. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens. 2010 Jul. 36 (4):210-4. [Medline].
Diao H, She Z, Cao D, Wang Z, Lin Z. Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis. Adv Ther. 2012 Jul. 29 (7):645-53. [Medline].
Lai Y, Sundar G, Ray M. Surgical treatment outcome of medically refractory huge giant papillary conjunctivitis. Am J Ophthalmol Case Rep. 2017 Dec. 8:22-24. [Medline].
Kruger CJ, Ehlers WH, Luistro AE, Donshik PC. Treatment of giant papillary conjunctivitis with cromolyn sodium. CLAO J. 1992 Jan. 18(1):46-8. [Medline].
Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea. 2008 Feb. 27 (2):228-9. [Medline].
La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013 Mar 14. 39:18. [Medline].
Irani AM, Burtus I, Tabbar KF, et al. Human conjunctival mast cells; distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol. 1990. 86(1):34-40.
Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Biol Med. 2015 Aug. 6 (Suppl 1):S10-2. [Medline].
Karen K Yeung, OD, FAAO Senior Optometrist, Arthur Ashe Student Health and Wellness Center, University of California, Los Angeles
Karen K Yeung, OD, FAAO is a member of the following medical societies: American Academy of Optometry
Disclosure: Nothing to disclose.
Barry A Weissman, OD, PhD, FAAO Professor of Optometry, Southern California College of Optometry; Professor Emeritus of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine
Barry A Weissman, OD, PhD, FAAO is a member of the following medical societies: American Academy of Optometry, American Optometric Association, California Optometric Society, International Society for Contact Lens Research
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Christopher J Rapuano, MD Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Hospital
Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery
Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cornea Society, AAO, OMIC, Allergan; Avedro; Bio-Tissue; GSK, Novartis; Shire; Sun Ophthalmics; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Avedro; Bio-Tissue; Shire.
Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Disclosure: Nothing to disclose.
Giant Papillary Conjunctivitis
Research & References of Giant Papillary Conjunctivitis|A&C Accounting And Tax Services